PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
G. sinense polysaccharide (GSP) tablet is approved by the SFDA in China as an adjunctive therapeutic drug for treating leukopenia and hematopoietic injury caused by concurrent chemo/radiation therapy during cancer treatment [PMID:31030747, PMID:29078264].
Pharmacological studies indicate antitumor effects; specifically, GSP70-2 showed suppression of tumor growth in 4T1 tumor-bearing mouse models [PMID:37903715, PMID:40733790].
The purified polysaccharide GSBP-2 selectively inhibited the proliferation, migration, and invasion of MDA-MB-231 cells in vitro [PMID:38688342].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 31030747 (2019) — Ganoderma sinense polysaccharide: An adjunctive drug used for cancer treatment. · Progress in molecular biology and translational science
- 2.PMID: 25975187 (2015) — Secondary metabolites from Ganoderma. · Phytochemistry
- 3.PMID: 39178996 (2024) — Comparative genomics reveals ample evidence to Ganoderma sinense cultivars for molecular identification and new FIP exploration. · Genomics
- 4.PMID: 40733790 (2025) — Structural feature and antitumor activity of a N-acetylglucosamine containing polysaccharide from Ganoderma sinense. · Carbohydrate polymers
- 5.PMID: 37903715 (2023) — A Comprehensive Review on the Chemical Composition, Pharmacology and Clinical Applications of Ganoderma.